NSGO-OV-UMB1/ENGOT-OV30: A phase II study of durvalumab in combination with the anti-CD73 monoclonal antibody Oleclumab in patients with relapsed ovarian cancer
M.R. Mirza, Line Bjørge(Haukeland University Hospital)
Cited by 12
Related Papers
Epigenome-based cancer risk prediction: rationale, opportunities and challenges
|Nature Reviews Clinical Oncology|2018|173
A phase 1b, multicentre, dose escalation, safety and pharmacokinetics study of tilvestamab (BGB149) in relapsed, platinum-resistant, high-grade serous ovarian cancer (PROC) patients
|British Journal of Cancer|2025|2
PR070/#391 Phase I trial of tilvestamab, a function-blocking antibody inhibiting AXL, in platinum-resistant/refractory high grade serous ovarian cancer (PROC)
|International Journal of Gynecological Cancer|2023|1